These nanoparticles, combined with anti-PD-L1 therapy, effectively induce immunogenic cell death and significantly enhance systemic antitumor immunity, preventing metastasis and tumor recurrence (Figure 4C) [127]. Here, CD274 is linked to neoplasm.